Dana-Farber Cancer Institute - Harvard Medical School

Dynamic Cell Therapies is a preclinical-stage biopharmaceutical company that develops advanced chimeric antigen receptor (CAR) T-cell technologies for the treatment of cancers and autoimmune diseases. The company specializes in creating redirectable CAR T-cell platforms and private cytokine signaling systems, which it has licensed from the Dana-Farber Cancer Institute. These technologies are designed to enhance the precision and effectiveness of immunotherapy by allowing CAR-T cells to attack specific tumor targets while minimizing systemic toxicity and improving memory cell populations to ensure durable therapeutic responses.

The company's work aims to address significant unmet medical needs in oncology, particularly for patients with hematological cancers such as multiple myeloma. By optimizing the identity and activity of engineered T-cells, Dynamic Cell Therapies seeks to produce safer and more potent alternatives to existing treatments. Based in Massachusetts, the startup has secured financial support from the Myeloma Investment Fund and is supported by a team of scientific and business advisors as it progresses its research toward clinical application.